Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Other Accumulated Expenses (2019 - 2025)

Historic Other Accumulated Expenses for 4D Molecular Therapeutics (FDMT) over the last 7 years, with Q3 2025 value amounting to $108000.0.

  • 4D Molecular Therapeutics' Other Accumulated Expenses fell 1360.0% to $108000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $108000.0, marking a year-over-year decrease of 1360.0%. This contributed to the annual value of $114000.0 for FY2024, which is 961.54% up from last year.
  • According to the latest figures from Q3 2025, 4D Molecular Therapeutics' Other Accumulated Expenses is $108000.0, which was down 1360.0% from $102000.0 recorded in Q2 2025.
  • Over the past 5 years, 4D Molecular Therapeutics' Other Accumulated Expenses peaked at $1.8 million during Q4 2021, and registered a low of $45000.0 during Q1 2023.
  • In the last 5 years, 4D Molecular Therapeutics' Other Accumulated Expenses had a median value of $161000.0 in 2025 and averaged $293894.7.
  • As far as peak fluctuations go, 4D Molecular Therapeutics' Other Accumulated Expenses surged by 26048.88% in 2021, and later tumbled by 9318.18% in 2023.
  • Over the past 5 years, 4D Molecular Therapeutics' Other Accumulated Expenses (Quarter) stood at $1.8 million in 2021, then crashed by 78.42% to $382000.0 in 2022, then plummeted by 72.77% to $104000.0 in 2023, then increased by 9.62% to $114000.0 in 2024, then decreased by 5.26% to $108000.0 in 2025.
  • Its Other Accumulated Expenses stands at $108000.0 for Q3 2025, versus $102000.0 for Q2 2025 and $161000.0 for Q1 2025.